Citation
Ji, Young Sok, et al. "Does Anti-thymocyte Globulin Have a Place in Busulfan/fludarabine Conditioning for Matched Related Donor Hematopoietic Stem Cell Transplantation?" The Korean Journal of Internal Medicine, vol. 31, no. 4, 2016, pp. 750-61.
Ji YS, Lee MS, Min CW, et al. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? Korean J Intern Med. 2016;31(4):750-61.
Ji, Y. S., Lee, M. S., Min, C. W., Park, S. K., Kim, S. H., Yun, J., Kim, H. J., Kim, K. H., Kim, C. K., Lee, K. T., Won, J. H., & Hong, D. S. (2016). Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? The Korean Journal of Internal Medicine, 31(4), 750-61. https://doi.org/10.3904/kjim.2015.234
Ji YS, et al. Does Anti-thymocyte Globulin Have a Place in Busulfan/fludarabine Conditioning for Matched Related Donor Hematopoietic Stem Cell Transplantation. Korean J Intern Med. 2016;31(4):750-61. PubMed PMID: 27017944.
TY - JOUR
T1 - Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
AU - Ji,Young Sok,
AU - Lee,Min Sung,
AU - Min,Chang Wook,
AU - Park,Seong Kyu,
AU - Kim,Se Hyung,
AU - Yun,Jina,
AU - Kim,Hyun Jung,
AU - Kim,Kyoung Ha,
AU - Kim,Chan Kyu,
AU - Lee,Kyu-Taek,
AU - Won,Jong-Ho,
AU - Hong,Dae Sik,
Y1 - 2016/03/28/
PY - 2015/07/22/received
PY - 2015/09/06/revised
PY - 2015/09/13/accepted
PY - 2016/3/29/entrez
PY - 2016/3/29/pubmed
PY - 2017/5/16/medline
KW - Antithymocyte globulin
KW - Fludarabine
KW - Graft vs host disease
KW - Hematopoietic stem cell transplantation
KW - Related donor
SP - 750
EP - 61
JF - The Korean journal of internal medicine
JO - Korean J Intern Med
VL - 31
IS - 4
N2 - BACKGROUND/AIMS: There is controversy about the prophylactic effect of anti-thymocyte globulin (ATG) on graft versus host disease (GVHD) in the setting of matched related-donor hematopoietic stem cell transplantation (HSCT). This study assessed the inf luences of ATG on the incidences of acute and chronic GVHD and other clinical outcomes in matched related-donor HSCT. METHODS: Sixty-one patients received allogeneic HSCT from human leukocyte antigen-matched, related donors. Patients received busulfan/fludarabine conditioning regimens and standard GVHD prophylaxis with or without additional ATG. RESULTS: There was no significant difference in the cumulative incidences of overall acute GVHD, grade II to IV acute GVHD at day 100, and chronic GVHD during the follow-up period between the ATG and non-ATG groups. Three-year overall survival rates were very similar, but three year disease-free survival of the non-ATG group was higher than that of the ATG group (56.2% for ATG vs. 63.1% for non-ATG, p = 0.597). Relapse rate at 3 years in the ATG group was slightly higher than that of the non-ATG group (37.5% vs. 20%, p = 0.29). Non-relapse mortality rate at 3 years was lower in the ATG group (6.25% vs. 15.6%, p = 0.668). CONCLUSIONS: Although the addition of ATG doesn't guarantee a reduction in the incidences of acute and chronic GVHD, pre-transplantation ATG may result in lower non-relapse mortality in the context of matched related-donor HSCT with a busulfan/fludarabine conditioning regimen. However, caution is needed when using ATG because of a possibility to increase relapse rate.
SN - 2005-6648
UR - https://www.unboundmedicine.com/medline/citation/27017944/Does_anti_thymocyte_globulin_have_a_place_in_busulfan/fludarabine_conditioning_for_matched_related_donor_hematopoietic_stem_cell_transplantation
L2 - https://dx.doi.org/10.3904/kjim.2015.234
DB - PRIME
DP - Unbound Medicine
ER -